Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma
Sponsor: Genentech, Inc.
A PHASE2 clinical study on Giant Cell Glioblastoma and Glioblastoma, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 14 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Mar 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Jonsson Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .